[Click e-Stock] "Boronoi, Preclinical Results Reconfirmed in Clinical Trials"

Yuanta Securities stated on April 28 that Boronoi has released the first clinical results for VRN11 (EGFR TKI), presenting data that supports its preclinical findings.

Ha Hyunsu, a researcher at Yuanta Securities, explained, "Most of the patients in the VRN11 clinical trial, which was presented at the American Association for Cancer Research (AACR), the world's largest cancer conference held in Chicago, had previously undergone four or more lines of treatment," adding, "It is believed that these patients had high tumor heterogeneity."

He continued, "There was one case involving a C797S patient," and added, "A meaningful result was observed in the C797S patient, who showed an unconfirmed partial response (uPR)."

He emphasized, "There were seven patients with brain metastases, and in six of them (one with partial response and five with stable disease), the tumor size did not increase, resulting in a disease control rate (DCR) of 85.7%," and added, "A partial response was observed in patients with fewer prior treatments, while the patient with progressive disease (PD) was in the ninth line of treatment, likely indicating high heterogeneity."

He further analyzed, "From a safety perspective, there were zero cases of Grade 2 or higher adverse events, which is a very encouraging result," and added, "Grade 1 adverse events were observed in six patients, but Grade 1 is either mild or asymptomatic and does not affect quality of life."

Researcher Ha stated, "The excellent selectivity of VRN11 has been reconfirmed with these safety results," and added, "Due to tumor heterogeneity, the importance of combination therapy in cancer treatment is increasing, and VRN11, with its excellent safety, is expected to offer a wide range of options when developing combination therapies."

He also predicted, "The clinical results for VRN11 have reconfirmed that the outstanding selectivity and brain penetration observed in previous preclinical studies are being replicated in clinical settings," and added, "VRN11 is currently undergoing both dose escalation and dose expansion studies, and future clinical announcements will include data from a larger patient population."